MP20-01 WATER vs WATER II 3-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80 cc and 80-150 cc Prostates

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology I (MP20)1 May 2024MP20-01 WATER vs WATER II 3-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80 cc and 80-150 cc Prostates Mohamad Baker Berjaoui, David-Dan Nguyen, Saud Almousa, Neil Barber, Mo Bidair, Peter Gilling, Paul Anderson, Kevin C. Zorn, Gopal Badlani, Mitch Humphreys, Steven Kaplan, Ronald Kaufman, Dean Elterman, Mihir Desai, Claus Roehrbor, and Naeem Bhojani Mohamad Baker BerjaouiMohamad Baker Berjaoui , David-Dan NguyenDavid-Dan Nguyen , Saud AlmousaSaud Almousa , Neil BarberNeil Barber , Mo BidairMo Bidair , Peter GillingPeter Gilling , Paul AndersonPaul Anderson , Kevin C. ZornKevin C. Zorn , Gopal BadlaniGopal Badlani , Mitch HumphreysMitch Humphreys , Steven KaplanSteven Kaplan , Ronald KaufmanRonald Kaufman , Dean EltermanDean Elterman , Mihir DesaiMihir Desai , Claus RoehrborClaus Roehrbor , and Naeem BhojaniNaeem Bhojani View All Author Informationhttps://doi.org/10.1097/01.JU.0001008732.80104.31.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Surgical options are limited when treating large (>80 cm3) prostates for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Aquablation has demonstrated comparable outcomes up to 3 years between small-to-moderate (30-80cc) and large (80-150 cc) prostates. We present the final analysis comparing clinical trial outcomes of Aquablation in small-to-moderate prostates to those in large prostates at 5 years of follow-up. METHODS: Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue (WATER; NCT02505919) is a prospective, double-blind, multicentre, international clinical trial comparing Aquablation and transurethral resection of the prostate (TURP) for the treatment of LUTS/BPH in prostates between 30 and 80 mL. WATER II (NCT03123250) is a prospective, multicentre, single-arm international clinical trial of Aquablation in prostates between 80 and 150 mL. We compare baseline parameters and 60-month outcomes in 116 WATER and 101 WATER II study patients that underwent Aquablation. Students' t-test or Wilcoxon tests were used for continuous variables and Fisher's test for binary variables. RESULTS: International Prostate Symptom Score (IPSS) scores improved from 22.9 and 23.2 at baseline in WATER and WATER II, respectively, to 7.0 and 6.8 at 60-month, with 60-month reductions of 15.9 and 16.4 points, respectively (p=0.85). At baseline, urinary flow rate (Qmax) was 9.4 and 8.7 cc/sec in WATER and WATER II, improving to 17.3 and 17.1 cc/sec, respectively (p=0.93) at 60 months. Improvements in both IPSS and Qmax were immediate and sustained throughout follow-up. At 5 years, 99% and 94% of treated patients were BPH medication-free in WATER and WATER II, respectively (p=0.05). At 5 years, 95% and 97% of treated patients were free from surgical retreatment in WATER and WATER II, respectively (p=0.51). CONCLUSIONS: The final five-year follow-up analysis of two, prospective clinical trials demonstrate that Aquablation therapy has durable outcomes and low retreatment rates for the treatment of LUTS/BPH independently of prostate volume between 30-150ml prostates. Download PPT Source of Funding: PROCEPT BioRobotics © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e319 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Mohamad Baker Berjaoui More articles by this author David-Dan Nguyen More articles by this author Saud Almousa More articles by this author Neil Barber More articles by this author Mo Bidair More articles by this author Peter Gilling More articles by this author Paul Anderson More articles by this author Kevin C. Zorn More articles by this author Gopal Badlani More articles by this author Mitch Humphreys More articles by this author Steven Kaplan More articles by this author Ronald Kaufman More articles by this author Dean Elterman More articles by this author Mihir Desai More articles by this author Claus Roehrbor More articles by this author Naeem Bhojani More articles by this author Expand All Advertisement PDF downloadLoading ...